LONDON (ShareCast) - (Sharecast News) - Pharmaceutical company Futura Medical announced the completion of initial laboratory and optimisation work on a 'Dermasys' cannabidiol gel, dubbed 'CBD100', under the joint venture collaboration agreement with CBDerma Technology that was announced in September.
The AIM-traded firm said that, as part of a "robust" formulation process using "strict" pharmaceutical development principles, Futura carried out extensive Dermasys cannabidiol formulation work and initial in vitro tests on human epidermis.

It said the studies demonstrated "highly efficient penetration" of cannabidiol into and through the skin, superior to an established, marketed comparator product.

Additionally, it said cannabidiol was known to be unstable with many common excipients.

The Dermasys cannabidiol gel was formulated to minimise that issue, and was reportedly showing "encouraging" early stability work, which was expected to ensure potency was retained during shelf-life.

"Our research and development team's development work on CBD100 is further evidence of the broad utility and power of the Dermasys system for effective and controlled transdermal delivery of a wide range of active pharmaceutical ingredients," said chief executive officer James Barder.

"We are aiming for CBD100 to be highly differentiated from existing, largely unregulated, low-tech products in the fast growing cannabidiol market on the basis of quality, stability and efficient delivery to the skin for a number of applications and indications expected to range from cosmeceutical through to pharmaceutical dermal and pain relief treatments.

"We have now started to explore commercialisation options for CBD100 with CBDerma as stability work continues in parallel."

At 1210 BST, shares in Futura Medical were up 5% at 15.75p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE